ReviewJournal of neurology2026
Thrombolytic resistance: an important factor leading to the failure of intravenous thrombolytic therapy.
Review in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acute ischemic stroke (AIS) is one of the most common nervous system diseases. Its high mortality and disability rates not only seriously threaten patients' health but also impose a significant socioeconomic burden. Intravenous thrombolysis (IVT) is the first-line treatment for AIS, and tissue-type plasminogen activator (t-PA) is the primary agent used in IVT. With the extension of the therapeutic time window, more AIS patients are eligible to receive t-PA treatment. The existence of thrombolytic resistance severely compromises the clinical efficacy of t-PA in AIS treatment. This paper elaborates on the phenomenon of thrombolytic resistance and analyzes the roles of thrombus components such as red blood cells (RBCs), platelets (PLTs), white blood cells (WBCs), and neutrophil extracellular traps (NETs), as well as non-thrombotic factors such as metabolic syndrome (MetS) and fatty acid (FA) in contributing to thrombolytic resistance. By clarifying the underlying mechanisms of thrombolytic resistance, this work aims to provide insights for strategies to overcome thrombolytic resistance and improve the therapeutic efficacy of t-PA.
Indexed as
Identifiers
42545430What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.